# The Optimal Radioimmunotherapy Combinations for Advanced TNBC

Source: https://onco.cc/trials/nct06735131/  
OnCo record `nct06735131` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of toripalimab in triple-negative breast cancer, run by Sun Yat-sen University, now recruiting.

## Summary

The Optimal Radioimmunotherapy Combinations for Advanced TNBC is a phase 2, interventional study registered as NCT06735131 by Sun Yat-sen University, with a registry enrolment figure of 60 participants, started 2024-12-20 and due to reach its primary completion in 2026-07. Interventions recorded: radiotherapy 5 Gy × 5 fractions, once a day; radiotherapy 8 Gy × 5 fractions, once a day; radiotherapy 8 Gy × 3 fractions, once every other day; radiotherapy 10 Gy× 3 fractions, once every other day; radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy); Toripalimab; chemotherapy regimen selected by the investigator. Conditions listed: Triple-Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: "Inoperable locally advanced/metastatic triple-negative breast cancer (defined as ER and PR \<1%; and HER2 negative as IHC 0 or IHC 1+, or IHC 2+ but negative upon fluorescence in situ hybridization (FISH) testing)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06735131
- Phase: 2
- Setting: A Prospective, Multicenter Clinical Trial Exploring the Optimal Combination Strategies of Radiotherapy and Immunotherapy for Advanced Triple-Negative Breast Cancer
- Sponsor: Sun Yat-sen University
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06735131: https://clinicaltrials.gov/study/NCT06735131

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06735131.json